Viatris Inc. has announced positive top-line results from the VEGA-3 trial, the second pivotal Phase 3 study evaluating MR-141 (phentolamine ophthalmic solution 0.75%) for treating presbyopia. The trial met its primary and all secondary endpoints, demonstrating rapid and sustained improvement in near visual acuity without compromising distance vision. The safety profile was consistent with previous clinical trials, with no treatment-related serious adverse events reported. The study involved 545 patients and showed significant improvements in visual acuity compared to placebo. Viatris plans to submit an application to the U.S. FDA in the second half of 2025. Results from this study have already been presented.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。